MedTrace Logo

Comparison of Ectoin® Containing Eye Drops and Ectoin® Containing Eye Spray With the Eye Spray Tears Again®

NCT04021225 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-08-11

No results posted yet for this study

Summary

This study aims to gain knowledge on the duration of symptom relief of environmental disorders of the eye as might be present in allergy sufferers after allergen exposure following application of the study products.

Additionally, the extent of symptom relief as well as tolerability of this topic treatment will be evaluated.

Conditions

  • Eye Manifestations

Interventions

DEVICE

Ectoin® Allergy Eye Drops 2%

A one-time application of 1-2 drops in the more affected eye will be investigated.

DEVICE

Ectoin® Eye Spray Colloidal

A one-time application of 1-2 drops in the more affected eye will be investigated.

DEVICE

Tears Again® eye spray

A one-time application of 1-2 drops in the more affected eye will be investigated.

Sponsors & Collaborators

  • Bitop AG

    lead INDUSTRY

Principal Investigators

  • Ralph Mösges, Dr. · ClinCompetence

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2019-06-28
Completion
2019-06-28

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04021225 on ClinicalTrials.gov